Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance hemodialysis

Nephron - Clinical Practice

Volumn 124, Issue 3-4, 2013, Pages 218-223

  Lai, Yu Cheng ^a   Cheng, Ben Chung ^a   Hwang, Jyh Chang ^b   Lee, Yueh Ting ^a   Chiu, Chien Hua ^a   Kuo, Li Chueh ^a   Chen, Jin Bor ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cardiovascular event; Fatty liver disease; Hemodialysis

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; FATTY LIVER; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; MAINTENANCE HEMODIALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; TAIWAN; END STAGE RENAL DISEASE; HEMODIALYSIS PATIENT; MAINTENANCE THERAPY; MIDDLE AGED; PREVALENCE; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FATTY LIVER; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84893645839     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000357952     Document Type: Article

References (27)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952. (Pubitemid 39208455)
2. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615. (Pubitemid 29297538)
3. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
4. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362. (Pubitemid 30429882)
5. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80: 99-102.
6. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK: Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 721-727.
7. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138. (Pubitemid 32880350)
8. Takahashi H, Ishii H, Aoyama T, Kamoi D, Kasuga H, Ito Y, Yasuda K, Tanaka M, Yoshikawa D, Maruyama S, Matsuo S, Murohara T, Yuzawa Y: Association of cardiac valvular calcifications and C-reactive protein with cardiovascular mortality in incident hemodialysis patients: a Japanese cohort study. Am J Kidney Dis 2013; 61: 254-261.
9. Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG: Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton) 2003; 8: 177-183. (Pubitemid 36995087)
10. Shen Y, Peake PW, Kelly JJ: Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005; 10: 599-605. (Pubitemid 41801842)
11. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
12. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B: Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544.
13. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M: Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139: 43-50. (Pubitemid 13164807)
14. Farrell GC, Chitturi S, Lau GK, Sollano JD: Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22: 775-777. (Pubitemid 46911045)
15. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G: Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006; 23: 403-409.
16. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C: Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46: 1126-1132. (Pubitemid 46669732)
17. Ahmed MH, Abu EO, Byrne CD: Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010; 4: 129-137.
18. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-3546. (Pubitemid 43334347)
19. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218. (Pubitemid 46684650)
20. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E: Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest 2012; 35: 215-218.
21. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S: Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 72-78.
22. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.
23. Cortez-Pinto H, de Moura MC, Day CP: Nonalcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006; 44: 197-208. (Pubitemid 41772535)
24. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911. (Pubitemid 29197978)
25. Stefan N, Kantartzis K, Häring HU: Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-960.
26. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219. (Pubitemid 36538699)
27. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.